XTX Topco Ltd Sells 162,940 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

XTX Topco Ltd trimmed its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 77.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 47,672 shares of the company's stock after selling 162,940 shares during the period. XTX Topco Ltd owned 0.07% of Amylyx Pharmaceuticals worth $154,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. AQR Capital Management LLC increased its stake in Amylyx Pharmaceuticals by 2,768.0% during the 2nd quarter. AQR Capital Management LLC now owns 3,340,943 shares of the company's stock valued at $6,348,000 after buying an additional 3,224,454 shares during the period. Almitas Capital LLC acquired a new position in shares of Amylyx Pharmaceuticals during the second quarter valued at approximately $3,617,000. abrdn plc raised its holdings in Amylyx Pharmaceuticals by 1,567.9% during the third quarter. abrdn plc now owns 1,972,242 shares of the company's stock worth $6,390,000 after purchasing an additional 1,853,995 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Amylyx Pharmaceuticals in the second quarter worth approximately $2,300,000. Finally, Alpha Wave Global LP bought a new position in Amylyx Pharmaceuticals during the 3rd quarter valued at $2,169,000. Institutional investors own 95.84% of the company's stock.

Amylyx Pharmaceuticals Price Performance

NASDAQ AMLX traded up $0.09 on Friday, hitting $4.05. 550,776 shares of the stock were exchanged, compared to its average volume of 1,921,250. The company's 50-day moving average price is $5.09 and its two-hundred day moving average price is $3.22. Amylyx Pharmaceuticals, Inc. has a 52-week low of $1.58 and a 52-week high of $19.95. The company has a market capitalization of $277.62 million, a price-to-earnings ratio of -1.06 and a beta of -0.68.

Insider Transactions at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, insider Camille L. Bedrosian sold 11,442 shares of the stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $3.20, for a total value of $36,614.40. Following the completion of the sale, the insider now owns 143,801 shares in the company, valued at $460,163.20. This represents a 7.37 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Justin B. Klee sold 18,589 shares of Amylyx Pharmaceuticals stock in a transaction on Monday, September 30th. The shares were sold at an average price of $3.20, for a total transaction of $59,484.80. Following the sale, the chief executive officer now directly owns 3,120,569 shares of the company's stock, valued at $9,985,820.80. This trade represents a 0.59 % decrease in their position. The disclosure for this sale can be found here. 11.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on AMLX shares. Robert W. Baird upgraded Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and upped their price objective for the company from $3.00 to $11.00 in a report on Monday, November 18th. HC Wainwright restated a "buy" rating and set a $12.00 price objective on shares of Amylyx Pharmaceuticals in a research report on Thursday, December 5th. Leerink Partners set a $4.00 target price on shares of Amylyx Pharmaceuticals and gave the stock a "market perform" rating in a report on Friday, October 18th. Baird R W upgraded shares of Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Monday, November 18th. Finally, Bank of America raised Amylyx Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their price target for the company from $4.20 to $10.00 in a report on Wednesday, October 23rd. Five research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $7.33.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.